Core Viewpoint - Junsheng Tai Pharmaceutical-B reported a significant reduction in losses for the first half of 2025, with a loss of 113.9 million yuan compared to a loss of 210.9 million yuan in the same period of 2024 [1] Group 1: Financial Performance - The company recorded a loss of 113.9 million yuan in the first half of 2025, which is a substantial improvement from the 210.9 million yuan loss in the first half of 2024 [1] Group 2: Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system, currently under development for CKM-related diseases [1] - HTD1801 is being developed for multiple conditions, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1] - A new indication for HTD1801 has been added for Chronic Kidney Disease, showing potential in regulating various pathogenic mechanisms related to kidney diseases [1] - HTD1801 demonstrates significant therapeutic potential in the CKD field, with advantages in improving eGFR (estimated Glomerular Filtration Rate) trends compared to competing drugs [1] - The company is preparing for a Phase II clinical study of HTD1801 for the treatment of CKD [1] Group 3: Pipeline Candidates - In addition to HTD1801, the company has developed a strong pipeline of innovative candidate drugs, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications [1]
君圣泰医药中期亏损大幅收窄 核心产品HTD1801新增适应症慢性肾病